Trisha Anne A. Arcilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Trisha Anne A. Arcilla has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Angel Mae D. Gregorio
Department of Biology, College of Science, Polytechnic University of the Philippines, Sta. Mesa, Manila 1016, Philippines
1 shared publication - Brian Harvey Avanceña Villanueva
International Degree Program in Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, Pingtung 912, Taiwan
1 shared publication - Cheska Jane A. Cudog
Department of Biology, College of Science, Polytechnic University of the Philippines, Sta. Mesa, Manila 1016, Philippines
1 shared publication - Eunice S. Salazar
Department of Biology, College of Science, Polytechnic University of the Philippines, Sta. Mesa, Manila 1016, Philippines
1 shared publication - Hoang Minh
Department of Anatomy and Histology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi 100000, Vietnam
1 shared publication - Huai-Ying Huang
Demin Veterinary Hospital, Kaohsiung 811, Taiwan
1 shared publication
Latest Publications
- Open Access
Mechanistic Insights into Off-the-Shelf vs. Personalized mRNA Cancer Vaccines: A Comparative Review of BNT111 and BNT122
MRNA vaccines are a relevant approach in cancer immunotherapy, using messenger RNA to induce immune responses against tumor-associated antigens. In this review, BNT111 and BNT122 are compared as representative off-the-shelf and personalized models. BNT111 is a fixed mRNA vaccine that has demonstrated significant antitumor efficacy against shared melanoma antigens, particularly when combined with immune checkpoint inhibitors. It allows a standardized production via in vitro transcription (IVT) in a cell-free system. Conversely, BNT122 is a personalized vaccine designed to match an individual’s tumor mutations by targeting patient-specific neoantigens to elicit more robust immune responses. It has significant suitability in the adjuvant setting to target minimal residual disease. Despite favorable safety and immunogenicity, the effectiveness of these vaccines is influenced by various factors, including tumor heterogeneity, differences in antigen expression, off-target effects on mRNA-LNP distribution, molecular instability, and complex manufacturing constraints. Neither approach can be directly considered as the definitive optimal vaccine. A comprehensive analysis of their strengths and limitations is vital for a balanced and objective future research direction. Collectively, this emphasizes the need for further improvements in vaccine design and strategies, prioritizing high-quality, safe, and accessible treatments for every cancer-based patient and ensuring their successful integration into healthcare.
Open AccessMechanistic Insights into Off-the-Shelf vs. Personalized mRNA Cancer Vaccines: A Comparative Review of BNT111 and BNT122
MRNA vaccines are a relevant approach in cancer immunotherapy, using messenger RNA to induce immune responses against tumor-associated antigens. In this review, BNT111 and BNT122 are compared as representative off-the-shelf and personalized models. BNT111 is a fixed mRNA vaccine that has demonstrated significant antitumor efficacy against shared melanoma antigens, particularly when combined with immune checkpoint inhibitors. It allows a standardized production via in vitro transcription (IVT) in a cell-free system. Conversely, BNT122 is a personalized vaccine designed to match an individual’s tumor mutations by targeting patient-specific neoantigens to elicit more robust immune responses. It has significant suitability in the adjuvant setting to target minimal residual disease. Despite favorable safety and immunogenicity, the effectiveness of these vaccines is influenced by various factors, including tumor heterogeneity, differences in antigen expression, off-target effects on mRNA-LNP distribution, molecular instability, and complex manufacturing constraints. Neither approach can be directly considered as the definitive optimal vaccine. A comprehensive analysis of their strengths and limitations is vital for a balanced and objective future research direction. Collectively, this emphasizes the need for further improvements in vaccine design and strategies, prioritizing high-quality, safe, and accessible treatments for every cancer-based patient and ensuring their successful integration into healthcare.